Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...
Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.
Jones Trading maintains Buy on ORIC, $17 target on positive data
Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...
Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
Investing4d
ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...